(“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA. This marks the first U.S. BLA acceptance for a ...

Class H ( (HK:2696)). Shanghai Henlius Biotech, Inc. announced that its biologics license application for HLX11, a biosimilar to Perjeta® (pertuzumab), has been accepted by the U.S. FDA.

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Shanghai Henlius Biotech, Inc. has achieved a significant milestone with the acceptance of their New Drug Application for ...

Hence, the rising incidence of breast cancer is a crucial driver of the growth of the herceptin biosimilars market. Who Are The Major Industry Players In The Perjeta Market ? Some of the prominent ...

Herceptin sales dropped a third in the first nine months of the year due in part to the pandemic but mainly the impact of low-cost biosimilars, although Perjeta remains in-patent for the next few ...

And these are the list of trastuzumab based biosimilars. There are five of them. And there's also a subq version of a combination of trastuzumab and pertuzumab, which is manufactured by Genentech.